Rigel Pharmaceuticals (RIGL) Other Accumulated Expenses (2010 - 2026)

Rigel Pharmaceuticals' Other Accumulated Expenses history runs 17 years deep, the most recent figure standing at $9.7 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 29.99% year-over-year to $9.7 million; the TTM figure through Mar 2026 stood at $9.7 million (up 29.99% YoY), while the FY2025 annual figure was $11.5 million, down 2.43% from the prior year.
• Other Accumulated Expenses was $9.7 million for Q1 2026 at Rigel Pharmaceuticals, down from $11.5 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $17.6 million in Q3 2022 to a low of $4.8 million in Q3 2023.
• Historically, Other Accumulated Expenses has averaged $9.0 million across 5 years, with a median of $8.6 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses soared 201.63% in 2022, then plunged 72.58% in 2023.
• A 5-year view of Other Accumulated Expenses shows it stood at $6.5 million in 2022, then dropped by 17.75% to $5.3 million in 2023, then surged by 120.3% to $11.8 million in 2024, then declined by 2.43% to $11.5 million in 2025, then declined by 15.63% to $9.7 million in 2026.
• The last three Other Accumulated Expenses figures came in at $9.7 million (Q1 2026), $11.5 million (Q4 2025), and $8.9 million (Q3 2025), per Business Quant data.